Quarterly Injectable Treatment for Prostate Cancer
For men with prostate cancer requiring androgen deprivation therapy (ADT), the primary quarterly (3-month) injectable options are triptorelin 11.25 mg and leuprolide 22.5 mg, both administered every 3 months via intramuscular or subcutaneous injection. 1
Standard ADT Formulations by Dosing Interval
The evidence supports multiple dosing intervals for LHRH agonists, with quarterly injections representing a middle-ground option:
Available Quarterly Formulations:
- Triptorelin 11.25 mg every 3 months - Achieves testosterone suppression to <20 ng/dL in 83-93% of patients 2
- Leuprolide 22.5 mg every 3 months - Demonstrated equivalent efficacy to other formulations 3
Alternative Dosing Intervals:
- Monthly injections: More frequent monitoring but higher treatment burden
- 6-monthly formulations: Triptorelin 22.5 mg or leuprolide 30 mg - Achieve comparable testosterone suppression (65-97% reaching <20 ng/dL) with less frequent administration 2, 3
Clinical Context for ADT Selection
ADT must be continued indefinitely regardless of disease progression or additional therapies added. 4 This applies across all disease states:
- Metastatic castration-sensitive disease: ADT should be combined with intensification therapy (docetaxel, abiraterone, enzalutamide, or apalutamide) 5
- Metastatic castration-resistant disease: Continue ADT while adding sequential therapies (abiraterone, enzalutamide, docetaxel, cabazitaxel, or radium-223) 4
Patient Preference Data
Recent evidence reveals important considerations for shared decision-making:
- 61% of patients prefer 6-monthly injections when efficacy and side effects are equivalent 6
- 38% prefer daily oral therapy (such as relugolix) over any injectable formulation 6
- Only 1% prefer monthly injections 6
- Patients with polypharmacy (>5 medications) significantly favor injections over oral therapy (p=0.025) 6
Practical Algorithm for Selecting Injection Frequency
Start with patient-specific factors:
Assess cardiovascular risk: If significant cardiovascular comorbidities exist, consider oral GnRH antagonist (relugolix) which reduces major cardiovascular events by 54% compared to leuprolide 7
Evaluate patient preference and logistics:
- Lives far from clinic → 6-monthly formulation
- Prefers more frequent monitoring → 3-monthly formulation
- Takes multiple daily medications → favor injectable over oral
- Desires flexibility/rapid testosterone recovery → oral relugolix (52% recovery vs 16% with injectables) 7
Consider disease characteristics:
- Disease progression → patients significantly prefer more frequent treatment (OR 4.4) 8
- Stable disease → longer intervals acceptable
Critical Monitoring Requirements
Testosterone levels should be routinely monitored despite this being poorly implemented in practice 9. Target castration level is <50 ng/dL, though evidence suggests <20 ng/dL may provide additional benefit 2.
Common Pitfalls to Avoid
- Never discontinue ADT when adding new therapies for castration-resistant disease - this is a fundamental error that compromises outcomes 4, 9
- Do not assume all formulations achieve equivalent testosterone suppression - 6-monthly formulations show wider variability (65-97% success) compared to 3-monthly (83-93%) 2
- Avoid prescribing injection frequency without discussing patient preference - satisfaction rates are high (84%) when patients participate in decision-making 8
Emerging Considerations
While quarterly injections remain standard, oral relugolix represents a paradigm shift with superior cardiovascular safety, no testosterone flare, and faster testosterone recovery 7. For patients with cardiovascular comorbidities or strong preference for oral therapy, this should be discussed as an alternative to any injectable formulation 10.
The choice between 3-monthly versus 6-monthly injections should prioritize patient convenience and adherence, as both achieve adequate castration in the majority of patients 2, 3.